A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer.

ABSTRACT: Breast cancer is the most common cancer in women worldwide, affecting one in eight women in their lifetime. Taxane-based chemotherapy is routinely used in the treatment of breast cancer. The purpose of this study was to develop and validate a predictive biomarker to improve the benefit/risk ratio for that cytotoxic chemotherapy. We explicitly strived for a biomarker that enables secure translation into clinical practice. We used genome-wide gene expression data of the Hatzis et al. discovery cohort of 310 patients for biomarker development and three independent cohorts with a total of 567 breast cancer patients for validation. We were able to develop a biomarker signature that consists of just the three gene products ELF5, SCUBE2 and NFIB, measured on RNA level. Compared to Hatzis et al.,

SUBMITTER: Kallarackal J 

PROVIDER: S-EPMC7083332 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature